AX-2026-041751 · Selank · TFS lot TFS-{CAT}-1712

Section 1

Results

Measured against the index acceptance specification for the neuroactive and cognitive peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 30 min gradient, 214 nm	99.76	% area	≥ 99.0	PASS
Total impurities	RP-HPLC, sum of reported peaks	0.24	% area	≤ 1.0	PASS
Largest single impurity	RP-HPLC — des-Thr (−101 Da)	0.15	% area	≤ 1.00	PASS
Identity — theoretical monoisotopic mass	calculated from molecular formula	751.4402	Da	—	NOT TESTED
Identity — observed monoisotopic mass	LC-MS, high resolution (ESI-TOF/QTOF)	751.4394	Da	—	NOT TESTED
Mass accuracy	observed vs theoretical	-1.0	ppm	± 15	PASS
Total peptide content	by difference from the gravimetric mass balance	86.64	%w/w	—	NOT TESTED
Target-compound content	total peptide content × purity	86.43	%w/w	—	NOT TESTED
Gross fill (as weighed)	five-place balance, under nitrogen	20.81	mg	20 mg declared	NOT TESTED
Recovered target peptide	gross fill × target content	17.986	mg	20 mg claim	NOT TESTED
Recovery against label claim	recovered ÷ claim	89.9	%	90.0 – 110.0	FAIL
Water content	Karl Fischer, coulometric, duplicate	8.19	%	≤ 12.0	PASS
Counter-ion (acetate)	anion-exchange ion chromatography	4.95	%	≤ 10.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.22	%	—	NOT TESTED
Endotoxin	kinetic chromogenic LAL	0.30	EU/mg	≤ 5.0	PASS
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	White lyophilised cake, intact	—	white to off-white intact cake	PASS
Reconstitution clarity	reconstituted per submitter procedure	Clear, colourless, no visible particulates	—	clear, no visible particulates	PASS
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	5.19	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 30 min gradient	5.59	min	6.42 ± 0.25 (normalised)	FAIL
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	1.01	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	61,740	—	≥ 20,000	PASS
Resolution to nearest impurity	vs diketopiperazine (−18 Da)	1.95	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 30 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 61,740, and skew follows the reported asymmetry factor of 1.01. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.15 % impurity against a 99.76 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	Selank — main peak	5.59	4,848,645	99.76	—
2	des-Thr (−101 Da)	5.33	7,290	0.15	-101.048
3	diketopiperazine (−18 Da)	5.77	2,430	0.05	-18.011
4	tuftsin fragment (−417 Da)	4.97	1,944	0.04	-417.235
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 3

Mass spectrum and identity

Theoretical monoisotopic mass 751.4402 Da, computed from C33H57N11O9. All ppm figures on this site are against monoisotopic values — see why that matters.

Figure 2. ESI charge-state envelope, high-resolution instrument. Sticks are placed at m/z = (M + z × 1.007276)/z for the observed neutral mass of 751.4394 Da. Sodium (+21.982/z) and potassium (+37.956/z) adducts are shown where the parent charge state exceeds 25 % relative abundance; they are adducts of the same molecule and are not impurities.

Charge	Theoretical m/z	Observed m/z	Δ m/z	Rel. abundance (%)
2+	376.7274	376.7270	-0.0004	54.2
1+	752.4475	752.4467	-0.0008	100.0

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Component	Determination	%w/w of cake
Water	Karl Fischer	8.19
Counter-ion (acetate)	ion chromatography	4.95
Residual solvent + inorganic residue	estimated	0.22
Total peptide content	by difference	86.64
Total		100.00 CLOSES

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	99.90	99.76	divergence +0.03 pp vs batch median
Total impurities (% area)	0.10	0.24
Largest single impurity (% area)	0.06	0.15
Water (%)	7.0	8.19
Counter-ion (%)	4.3	4.95
Peptide content (%w/w)	88.1	86.64
Endotoxin (EU/mg)	0.14	0.30
Method stated on certificate	YES	—	column, gradient and wavelength given

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Buyer-sourced
Evidentiary weight: Strongest available evidence in this index.
Chain of custody: Retail purchase → submitter (ambient, 34 d) → laboratory (courier, cold pack, 4 d) → assay.
Assay date: 17 May 2026
Submitted to the index: 28 May 2026
Laboratory: Janoshik Analytical, Ostrava, Czechia
Method basis: 30 min gradient · high-resolution MS
Verification status: VERIFIED

What this report does not establish

That the material is sterile. Sterility was not tested.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations 4

Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.

c18_2p628 May 2026

Column chemistry flatters or punishes a figure like this. A core-shell column at this gradient resolves the close-eluting family that a fully porous 5 µm bed merges, so 99.76 % here is a harder number than the same figure from a coarser column.

area_percent28 May 2026

Area percent assumes unit response factors across every species present. At 99.76 % the assumption barely matters — there is not enough impurity for a response-factor error to move the figure by a tenth.

gradient_2528 May 2026

The gradient is on the record, which is the first thing that should be true of any purity figure and often is not. 30 min at Janoshik puts this comparison on a documented footing.

retest_date28 May 2026

A retest date on the certificate would tell you what the supplier is actually asserting about stability. Purity at 99.76 % on assay day is a starting condition, not a shelf life.

Section 7

Related records

Same batch — lot TFS-{CAT}-1712 n=13

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-041752	TFS-{CAT}-1712	Medutest	2026-Q2	99.63	7.43	—	Buyer-sourced	1	FAIL
AX-2026-041753	TFS-{CAT}-1712	Janoshik	2026-Q2	99.67	7.48	92.6	Buyer-sourced	0	PASS
AX-2026-041754	TFS-{CAT}-1712	PeptideMeter	2026-Q2	99.93	7.49	—	Buyer-sourced	0	PASS
AX-2026-041755	TFS-{CAT}-1712	VendorInvestigate	2026-Q2	99.93	7.37	104.5	Buyer-sourced	0	PASS
AX-2026-041756	TFS-{CAT}-1712	PeptideMeter	2026-Q2	99.90	8.21	103.7	Buyer-sourced	0	PASS
AX-2026-041757	TFS-{CAT}-1712	Medutest	2026-Q2	99.93	7.54	—	Buyer-sourced	0	PASS
AX-2026-041758	TFS-{CAT}-1712	Janoshik	2026-Q2	99.78	8.10	97.6	Buyer-sourced	0	PASS
AX-2026-041759	TFS-{CAT}-1712	Janoshik	2026-Q2	99.93	8.13	102.2	Buyer-sourced	0	PASS
AX-2026-041760	TFS-{CAT}-1712	Janoshik	2026-Q2	99.82	7.70	—	Buyer-sourced	0	PASS
AX-2026-041761	TFS-{CAT}-1712	PeptideMeter	2026-Q2	99.93	7.79	91.8	Buyer-sourced	0	PASS
AX-2026-041762	TFS-{CAT}-1712	Janoshik	2026-Q2	99.75	7.24	—	Buyer-sourced	0	PASS
AX-2026-041763	TFS-{CAT}-1712	PeptideMeter	2026-Q2	99.87	8.20	—	Buyer-sourced	0	PASS

Batch rollup and reproducibility assessment →

Cross-sections

Other recent Selank records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-042858	GGPeps	GGPE-2603-J2447	VendorInvestigate	2026-Q3	98.87	8.85	99.4	Buyer-sourced	0	FAIL
AX-2026-042859	GGPeps	GGPE-2603-J2447	PeptideMeter	2026-Q3	98.92	9.48	103.5	Buyer-sourced	0	FAIL
AX-2026-041759	TFS	TFS-{CAT}-1712	Janoshik	2026-Q2	99.93	8.13	102.2	Buyer-sourced	0	PASS
AX-2026-042912	GGPeps	GGPE-2601-J3130	Janoshik	2026-Q2	99.75	9.44	89.7	Buyer-sourced	1	MARGINAL
AX-2026-041760	TFS	TFS-{CAT}-1712	Janoshik	2026-Q2	99.82	7.70	—	Buyer-sourced	0	PASS
AX-2026-041752	TFS	TFS-{CAT}-1712	Medutest	2026-Q2	99.63	7.43	—	Buyer-sourced	1	FAIL
AX-2026-042915	GGPeps	GGPE-2601-J3130	PeptideMeter	2026-Q2	99.53	10.03	—	Buyer-sourced	0	PASS
AX-2026-042910	GGPeps	GGPE-2601-J3130	VendorInvestigate	2026-Q2	99.62	9.21	105.0	Buyer-sourced	0	PASS

Other recent TFS records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-041681	CJC-1295 with DAC	TFS-{CAT}-9675	PeptideMeter	2026-Q3	98.82	3.67	—	Buyer-sourced	0	PASS
AX-2026-041766	BPC-157	TFS-{CAT}-1156	Janoshik	2026-Q3	99.54	6.34	—	Buyer-sourced	1	MARGINAL
AX-2026-041682	CJC-1295 with DAC	TFS-{CAT}-9675	Nordanalyt	2026-Q3	98.94	3.24	—	Buyer-sourced	0	PASS
AX-2026-041683	CJC-1295 with DAC	TFS-{CAT}-9675	Medutest	2026-Q3	98.68	3.46	97.0	Buyer-sourced	0	PASS
AX-2026-041765	BPC-157	TFS-{CAT}-1156	Janoshik	2026-Q3	99.79	6.01	—	Buyer-sourced	0	PASS
AX-2026-041680	CJC-1295 with DAC	TFS-{CAT}-9675	Medutest	2026-Q3	99.18	2.85	100.4	Buyer-sourced	0	PASS
AX-2026-041691	Semaglutide	TFS-{CAT}-9744	Janoshik	2026-Q2	98.31	6.07	91.4	Buyer-sourced	0	PASS
AX-2026-041700	SS-31 (Elamipretide)	TFS-{CAT}-1142	Medutest	2026-Q2	99.75	2.27	96.3	Buyer-sourced	0	PASS